Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARPAUL S GILL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1023158409
CMS profile
136717
Location
CYPRESS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,872.18

204 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,866.28 202
Education $5.90 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARPAUL S GILL

NPI 1023158409 · CMS profile ID 136717

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CYPRESS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023158409?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARPAUL S GILL, NPI 1023158409, CMS profile ID 136717. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023158409?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HARPAUL S GILL, NPI 1023158409, CMS profile ID 136717. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023158409?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HARPAUL S GILL, NPI 1023158409, CMS profile ID 136717, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 204 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1023158409?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

204 matching records · $3,872.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 204 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 204.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $14.0507/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124800564 CMS
Abbott Laboratories $15.8207/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124800566 CMS
ABBVIE INC. $5.8006/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797920 CMS
Eisai Inc. $23.5706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110748188 CMS
Alexion Pharmaceuticals, Inc. $23.1706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093930334 CMS
Genentech USA, Inc. $17.4606/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133018778 CMS
UCB, Inc. $26.4406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143068071 CMS
Lilly USA, LLC $20.0006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135014431 CMS
Biogen, Inc. $24.7706/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104819790 CMS
Biogen, Inc. $1.9606/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104823996 CMS
ABBVIE INC. $5.3906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797918 CMS
Amneal Pharmaceuticals LLC $20.0806/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139186772 CMS
Marinus Pharmaceuticals, Inc. $19.7106/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141323686 CMS
UCB, Inc. $6.4606/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143068069 CMS
Teva Pharmaceuticals USA, Inc. $20.9906/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151607074 CMS
Lilly USA, LLC $22.0606/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135021440 CMS
Acorda Therapeutics, Inc $13.6705/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142348400 CMS
Lundbeck LLC $22.6105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145918839 CMS
Neurocrine Biosciences, Inc. $23.0305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150846461 CMS
Novartis Pharmaceuticals Corporation $21.4405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086845991 CMS
SK Life Science, Inc. $23.7905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154113211 CMS
ABBVIE INC. $3.8305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797916 CMS
ARGENX US, INC. $29.8505/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142106800 CMS
Otsuka America Pharmaceutical, Inc. $4.9205/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118897972 CMS
UCB, Inc. $25.8305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143068067 CMS
ACADIA Pharmaceuticals Inc $1.3605/14/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147970566 CMS
ACADIA Pharmaceuticals Inc $21.1805/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147970568 CMS
Otsuka America Pharmaceutical, Inc. $9.6505/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118897970 CMS
ABBVIE INC. $8.7705/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797914 CMS
Biogen, Inc. $16.3405/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104828876 CMS
Lundbeck LLC $17.4605/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145918837 CMS
Celgene Corporation $21.1904/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101170538 CMS
ABBVIE INC. $6.1204/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797912 CMS
Alexion Pharmaceuticals, Inc. $28.2804/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093983926 CMS
Alexion Pharmaceuticals, Inc. $23.3604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094025429 CMS
Neurocrine Biosciences, Inc. $5.9104/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150887179 CMS
Novartis Pharmaceuticals Corporation $21.7604/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086845989 CMS
CATALYST PHARMACEUTICALS, INC. $31.7604/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144446450 CMS
SK Life Science, Inc. $25.8304/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154113189 CMS
ABBVIE INC. $6.6904/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797910 CMS
ACADIA Pharmaceuticals Inc $16.9304/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147970564 CMS
Neurocrine Biosciences, Inc. $18.1504/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150865045 CMS
UCB, Inc. $22.7804/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143068065 CMS
Abbott Laboratories $22.6504/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124800560 CMS
Abbott Laboratories $15.6304/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124800562 CMS
ABBVIE INC. $8.5204/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797908 CMS
Azurity Pharmaceuticals, Inc. $19.8104/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134006035 CMS
ABBVIE INC. $15.9004/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103797906 CMS
LivaNova USA, Inc. $21.5304/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152789661 CMS
UCB, Inc. $28.7704/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143068063 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,086.24 160
PY2020 $2,336.72 127
PY2021 $3,557.57 250
PY2022 $4,777.88 326
PY2023 $4,209.23 237
PY2024 $3,872.18 204
PY2025 $4,308.20 191

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $698,918.84 94
PY2024 Recipient $9,000.00 2
PY2024 Principal investigator $302,347.85 22
PY2023 Recipient $86,476.00 12
PY2023 Principal investigator $10,718.67 3
PY2022 Principal investigator $20,313.44 5
PY2021 Principal investigator $129,886.53 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,256.72 12/31/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease No dispute reported 06/30/2026 1202532390
Principal investigator 1 ARGENX US, INC. $14,735.25 12/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237150741
Principal investigator 1 ABBVIE INC. $3,500.00 12/05/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinsons Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202529270
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,257.00 12/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
ITI-1284-201 No dispute reported 06/30/2026 1242368311
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,777.00 12/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
ITI-1284-201 No dispute reported 06/30/2026 1242368313
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,065.00 12/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
ITI-1284-201 No dispute reported 06/30/2026 1242368315
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $483.00 12/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
ITI-1284-201 No dispute reported 06/30/2026 1242368317
Principal investigator 1 ABBVIE INC. $1,984.50 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202524690
Principal investigator 1 ABBVIE INC. $3,645.00 11/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202524696
Principal investigator 1 ABBVIE INC. $6,496.90 11/07/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202523589
Principal investigator 1 ABBVIE INC. $9,734.16 11/05/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202523149
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,415.00 11/03/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
ITI-1284-201 No dispute reported 06/30/2026 1242365197
Principal investigator 1 ABBVIE INC. $307.80 10/09/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202516481
Principal investigator 1 ABBVIE INC. $307.80 09/11/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202510804
Principal investigator 1 Celgene Corporation $26,200.00 09/03/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1222306665
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,497.76 08/26/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235996829
Principal investigator 1 ABBVIE INC. $2,968.99 08/13/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202504495
Principal investigator 1 ABBVIE INC. $7,887.15 08/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202503603
Principal investigator 1 ARGENX US, INC. $1,800.00 08/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237150734
Principal investigator 1 ARGENX US, INC. $2,750.00 08/01/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237150738
Principal investigator 1 ABBVIE INC. $715.00 07/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202499152
Principal investigator 1 ABBVIE INC. $307.80 07/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202499154
Principal investigator 1 GlaxoSmithKline, LLC. $1,834.08 07/10/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111448
Principal investigator 1 ABBVIE INC. $3,276.79 06/19/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202492451
Principal investigator 1 ARGENX US, INC. $21,000.00 06/18/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC No dispute reported 06/30/2026 1237150730
Principal investigator 1 ABBVIE INC. $14,947.21 06/17/2025 Non-covered Recipient Entity
GILL NEUROSCIENCE
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202491797
Principal investigator 1 ABBVIE INC. $10,000.00 06/13/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202491505
Principal investigator 1 ABBVIE INC. $4,000.00 06/05/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202490601
Principal investigator 1 ABBVIE INC. $1,080.00 06/05/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202490603
Principal investigator 1 ABBVIE INC. $1,515.00 06/05/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202490605
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,511.00 06/04/2025 Non-covered Recipient Entity
Northside Hospital Gwinnett
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations No dispute reported 06/30/2026 1235995269
Principal investigator 1 GlaxoSmithKline, LLC. $102.75 05/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192169560
Principal investigator 1 GlaxoSmithKline, LLC. $308.25 05/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170861
Principal investigator 1 GlaxoSmithKline, LLC. $308.25 05/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170866
Principal investigator 1 GlaxoSmithKline, LLC. $205.50 05/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170889
Principal investigator 1 ABBVIE INC. $121.50 05/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202486011
Principal investigator 1 ABBVIE INC. $500.00 05/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202486013
Principal investigator 1 ABBVIE INC. $2,032.76 05/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202486015
Principal investigator 1 ABBVIE INC. $135.00 05/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202486017
Principal investigator 1 ABBVIE INC. $324.00 05/22/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202486019
Principal investigator 1 GlaxoSmithKline, LLC. $438.40 05/14/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192119287
Principal investigator 1 GlaxoSmithKline, LLC. $137.00 05/14/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192171985
Principal investigator 1 GlaxoSmithKline, LLC. $986.40 05/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111418
Principal investigator 1 GlaxoSmithKline, LLC. $2,386.54 05/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111424
Principal investigator 1 GlaxoSmithKline, LLC. $1,263.14 05/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117130
Principal investigator 1 GlaxoSmithKline, LLC. $1,233.00 05/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117161
Principal investigator 1 GlaxoSmithKline, LLC. $4,549.77 05/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192119270
Principal investigator 1 GlaxoSmithKline, LLC. $3,789.42 05/12/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192172008
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $161,155.25 05/09/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235996833
Principal investigator 1 ABBVIE INC. $3,500.00 05/08/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202484565
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,137.12 05/08/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235996827
Principal investigator 1 GlaxoSmithKline, LLC. $123.30 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111402
Principal investigator 1 GlaxoSmithKline, LLC. $4,315.50 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111410
Principal investigator 1 GlaxoSmithKline, LLC. $1,109.70 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111430
Principal investigator 1 GlaxoSmithKline, LLC. $4,315.50 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111436
Principal investigator 1 GlaxoSmithKline, LLC. $863.10 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192111441
Principal investigator 1 GlaxoSmithKline, LLC. $348.20 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117123
Principal investigator 1 GlaxoSmithKline, LLC. $174.10 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117136
Principal investigator 1 GlaxoSmithKline, LLC. $2,466.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117142
Principal investigator 1 GlaxoSmithKline, LLC. $4,110.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117150
Principal investigator 1 GlaxoSmithKline, LLC. $123.30 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117156
Principal investigator 1 GlaxoSmithKline, LLC. $739.80 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117167
Principal investigator 1 GlaxoSmithKline, LLC. $3,699.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192117174
Principal investigator 1 GlaxoSmithKline, LLC. $2,055.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192119282
Principal investigator 1 GlaxoSmithKline, LLC. $616.50 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192169545
Principal investigator 1 GlaxoSmithKline, LLC. $616.50 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192169549
Principal investigator 1 GlaxoSmithKline, LLC. $1,370.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192169565
Principal investigator 1 GlaxoSmithKline, LLC. $616.50 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170875
Principal investigator 1 GlaxoSmithKline, LLC. $369.90 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170895
Principal investigator 1 GlaxoSmithKline, LLC. $2,466.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192171998
Principal investigator 1 GlaxoSmithKline, LLC. $2,740.00 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192172003
Principal investigator 1 GlaxoSmithKline, LLC. $8,014.50 04/29/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192172012
Principal investigator 1 ABBVIE INC. $4,750.00 04/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202479418
Principal investigator 1 ABBVIE INC. $2,968.99 04/17/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202477809
Principal investigator 1 GlaxoSmithKline, LLC. $2,397.50 03/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192171989
Principal investigator 1 ABBVIE INC. $2,802.26 03/13/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202463818
Principal investigator 1 ABBVIE INC. $10,022.73 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202459001
Principal investigator 1 ABBVIE INC. $13,338.00 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202459006
Principal investigator 1 ABBVIE INC. $3,000.00 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202459023
Principal investigator 1 ABBVIE INC. $3,500.00 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202459028
Principal investigator 1 ABBVIE INC. $1,500.00 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202459051
Principal investigator 1 ABBVIE INC. $1,000.00 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202459055
Principal investigator 1 ABBVIE INC. $1,500.00 03/06/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202459058
Principal investigator 1 GlaxoSmithKline, LLC. $2,243.38 02/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192119276
Principal investigator 1 GlaxoSmithKline, LLC. $1,644.00 02/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170884
Principal investigator 1 GlaxoSmithKline, LLC. $5,137.50 02/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192171980
Principal investigator 1 GlaxoSmithKline, LLC. $2,055.00 02/26/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192171994
Principal investigator 1 GlaxoSmithKline, LLC. $2,397.50 02/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192119264
Principal investigator 1 GlaxoSmithKline, LLC. $14,184.21 02/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192169552
Principal investigator 1 GlaxoSmithKline, LLC. $616.50 02/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192169557
Principal investigator 1 GlaxoSmithKline, LLC. $1,233.00 02/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170870
Principal investigator 1 GlaxoSmithKline, LLC. $1,233.00 02/24/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU No dispute reported 06/30/2026 1192170880
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $131,516.50 02/03/2025 Non-covered Recipient Entity
Horizon Clinical Research Group
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235996831
Principal investigator 1 ABBVIE INC. $91,756.41 01/16/2025 Non-covered Recipient Entity
HORIZON CLINICAL RESEARCH GROUP
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202439785